摘要
ＥＢ１０８９是１，２５－二羟维生素Ｄ３［１，２５（ＯＨ）２Ｄ３］的新型类似物。以新近建立的一株人原始巨核白血病细胞系（ＨＩＭｅｇ）为模型研究发现，在悬浮培养体系中，ＥＢ１０８９可以明显地抑制ＨＩＭｅｇ细胞的增殖过程，且具有时间和剂量依赖性特点，其效应明显强于１，２５（ＯＨ）２Ｄ３。克隆增殖实验表明，即使在极低浓度（１０－１０～１０－１３ｍｏｌ／Ｌ）时，ＥＢ１０８９也可明显抑制ＨＩＭｅｇ细胞的克隆增殖。免疫荧光分析显示，对照组只有约２％的细胞表达糖蛋白Ⅱｂ／Ⅲａ（ＧＰⅡｂ／Ⅲａ），但经ＥＢ１０８９或１，２５（ＯＨ）２Ｄ３处理４ｄ后分别有９０％和５０％的细胞表达ＧＰⅡｂ／Ⅲａ。实验结果表明，ＥＢ１０８９对ＨＩＭｅｇ细胞具有比１，２５（ＯＨ）２Ｄ３更强的抑制增殖和诱导分化作用。由于ＥＢ１０８９的钙磷代谢调节作用甚弱，因此具有潜在的临床应用价值。
Using a recently established human megakaryoblastic leukemia cell line,HIMeg,the proliferation and differentiation of megakaryocytic cells in the presence of EB1089,a novel 1,25-dihydroxyvitamin D3[1,25(OH)2D3] analogue,were investigated. In a liquid culture system,EB1089 could inhibit the proliferation of HIMeg cells in a dose-and time-dependent fashion,and the effect of EB1089 was found to be much more active than that of 1, 25(OH)2D3.In a methylcellulose culture system, EB1089 inhibited colony formation by HIMeg cells even at very low concentrations(10-10 to 10-13mo1/L).Immunofluorescence analysis showed that 2% of the HIMeg cells expressed glycoprotein Ⅱb/Ⅲa(GPⅡb/Ⅲa)antigen without vitamin D3 compounds, whereas 90% and 50% of the cells expressed GPⅡb/Ⅲa with the addition of EB1089 and 1,25(OH)2D3,respectivly. These observations suggest that, like 1,25(OH)2D3,EB1089 could play an important role in the proliferation and differentiation of cells of megakaryocytic lineage and might be of potentially therapeutical interest.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
1994年第4期301-305,共5页
Academic Journal of Second Military Medical University
基金
国家自然科学基金
关键词
EB1089
诱导分化
白血病
巨核细胞
dihydroxyvitamin D_3
EB1089
differentiation
leukemia
megakaryocytic lineage
